RA Capital Management SYRE Position
Active16-Fund ConvergenceRA Capital Management initiated a new position in Spyre Therapeutics, Inc. (SYRE) in Q4 2025, holding $53.1M worth of shares across 1,621,620 shares.
SYRE is a convergence signal: 16 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for SPY001 in 75 days (Jun 30, 2026), making the timing of RA Capital's position particularly relevant.
Short interest stands at 15.3% of float with 12.1 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Full company profile →Short Interest
15.3%
12.1 days to cover
Frequently Asked Questions
Does RA Capital Management own SYRE?
Yes. As of Q4 2025, RA Capital Management holds 1,621,620 shares of Spyre Therapeutics, Inc. (SYRE) valued at $53.1M. This data comes from their SEC 13F filing.
How many hedge funds own SYRE?
16 specialist biotech hedge funds currently hold SYRE, including RTW Investments, Perceptive Advisors, Driehaus Capital and 12 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy SYRE?
RA Capital Management's position in SYRE was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's SYRE position increasing or decreasing?
RA Capital Management initiated a new position in SYRE in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SYRECompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →